Production Linked Incentive (PLI) Scheme for Pharmaceutical

The scheme intends to boost domestic manufacturing of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs – PLI scheme for pharmaceutical industries

Quantum of Incentive:

Financial incentive under the scheme shall be provided on sales of 41 identified products for six (06) years at the rates given below:

  • For fermentation based products, incentive for FY 2023-24 to FY 2026-27 would be 20%, incentive for 2027-28 would be 15% and incentive for 2028-29 would be 5%
  • For chemical synthesis based products, incentive for FY 2022-23 to FY 2027-28 would be 10%.

Eligibility

 Support under the scheme shall be provided only to manufacturers of critical KSMs/DIs and APIs registered in India.

  • Eligibility shall be subject to threshold investment in green field projects
  • Eligibility under the scheme shall not affect eligibility under any other scheme and viceversa.

 Target Segments

  Fermentation based KSMs/Drug Intermediates

 1. Penicillin G

2. 7-ACA

3. Erythromycin Thiocynate (TIOC)

 4. Clavulanic Acid

II. Fermentation based niche KSMs/Drug Intermediates/APIs

5. Neomycin

6. Gentamycin

7. Betamethasone

 8. Dexamethasone

 9. Prednisolone

 10. Rifampicin

11. Vitamin B1

 12. Clindamycin Base

13. Streptomycin

 14. Tetracycline III. Key Chemical Synthesis based KSMs/Drug Intermediates

15. 1,1 Cyclohexane Diacetic Acid (CDA)

16. 2-Methyl-5Nitro-Imidazole (2-MNI)

17. Dicyandiamide (DCDA)

18. Para amino phenol IV. Other Chemical Synthesis based KSMs/Drug Intermediates/APIs

19. Meropenem

 20. Atorvastatin

21. Olmesartan

22. Valsartan

23. Losartan

 24. Levofloxacin

 25. Sulfadiazine

 26. Ciprofloxacn

27. Ofloxacin

28. Norfloxacin

29. Artesunate

30. Telmisartan

 31. Aspirin

32. Diclofenac Sodium

33. Levetiracetam

34. Carbidopa

 35. Ritonavir

36. Lopinavir

37. Acyclovir

 38. Carbamazepine

39. Oxcarbazepine

40. Vitamin B6

41. Levodop

Eligibility Threshold Criteria

S. No.. SegmentThreshold Investment
1 Fermentation based 04 KSMs /Drug IntermediatesRs. 400 crore
2Fermentation based 10 niche KSMs / Drug Intermediates / APIsRs. 50 crore
3Key Chemical Synthesis based 04 KSMs /Drug IntermediatesRs. 50 crore
4Other 23 Chemical Synthesis based KSMs / Drug Intermediates / APIsRs. 20 crore
PLI scheme for pharmaceutical industries

Tags: No tags

Add a Comment

Your email address will not be published. Required fields are marked *